MetP Pharma releases positive data on intranasal semaglutide administration
Ella Day | July 22, 2025 | News story | Research and Development | Diabetes, MetP Pharma, Neurology, Obesity, central nervous system, diabetes, obesity, peptides, semaglutide
MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering neuroactive peptides, particularly semaglutide, directly to the brain though the intranasal route. This opens up the possibility of the platform being used for a wide range of neuroactive therapeutics, from metabolic to neurodegenerative diseases.
The data demonstrates that the MetP platform significantly enhances the penetration of semaglutide though the central nervous system (CNS), enhancing the brain’s ability to mediate the drug’s weight-loss effects. Specifically, the technology allows rapid brain uptake, sustained CNS exposure and high brain-to-plasma ratio and minimal systemic exposure – potentially reducing peripheral side effects.
Currently, subcutaneous and oral formulations of semaglutide, widely used in weight-loss and diabetes care, are limited by poor oral bioavailability, gastrointestinal side effects, inconvenient administration and CNS penetration. Moreover, these methods are associated with muscle loss as a side effect. This makes administration directly to the brain more appealing.
The MetP technology “overcomes barriers by leveraging perineural and perivascular transport pathways, bypassing the blood-brain barrier and enabling direct, efficient brain delivery,” said Claudia Mattern, chief scientific officer of MetP Pharma.
MetP Pharma is a pharma and product development company based in Switzerland specialising in nose-to-brain drug delivery. It is developing intranasal therapeutics targeting conditions such as concussion, insomnia, ADHD, multiple sclerosis and hypogonadism.
Ella Day
22/7/25
Related Content
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
Lilly reports positive results from trial of obesity candidate
Eli Lilly and Company (Lilly) has announced topline results from its phase 3 ATTAIN-1 trial, …
Secarna and Vect-Horus collaborate to advance therapies for central nervous system disorders
Secarna Pharmaceuticals and Vect-Horus have announced that the companies will collaborate to develop RNA-targeted therapeutics …
